Search

Displaying results 3421 - 3430 of 9333 in total
  1. Drug

    ReN001

    go.drugbank.com/drugs/DB05236
    Investigational

    ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans … ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke.

  2. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    It has been approved for the treatment of insomnia.

  3. Drug

    Midomafetamine

    go.drugbank.com/drugs/DB01454
    IllicitInvestigational

    It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Canrenoic acid

    go.drugbank.com/drugs/DB09015
    ApprovedInvestigationalWithdrawn

    Canrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.

  5. Drug

    Prednisolone

    go.drugbank.com/drugs/DB00860
    ApprovedInvestigationalVet approved

    Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

    Synonyms: Predniso(lo)neProducts: SCHERISOLONA® TABLETAS DE 5 MG
  6. Drug

    Dexetimide

    go.drugbank.com/drugs/DB08997
    ApprovedWithdrawn

    A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.

  7. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway. … The FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with

  8. Drug

    Triclocarban

    go.drugbank.com/drugs/DB11155
    Approved

    In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer antiseptic wash products containing triclocarban due to negative health effects such as bacterial resistance or hormonal … Triclocarban, with the chemical formula C13H9Cl3N2O [L2675] is an antibacterial agent that is particularly effective against Gram-positive bacteria such as *Staphylococcus aureus*.

  9. Drug

    Cobalt

    go.drugbank.com/drugs/DB14574
    ApprovedWithdrawn

    Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis. … Except for radioactive forms of cobalt and cobalamin, the FDA withdrew its approval for the use of drug products containing cobalt salts.[L43942]

  10. Drug

    Thenalidine

    go.drugbank.com/drugs/DB04826
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.